Genomic Vision Stock

Genomic Vision Current Assets

The Current Assets of Genomic Vision (GV.PA) as of Sep 10, 2026 is 3.55 M EUR. In the previous year, Current Assets was 5.26 M EUR — a change of -32.46% (lower).

Current Assets

3.55 MEUR

YoY

-32.46%

Last updated:

Current Assets of Genomic Vision is 2026 3.55 M EUR. Current Assets of Genomic Vision was 2025 5.26 M EUR. It decreases by -32.46% lower compared to the previous year.

The Genomic Vision Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2015
18.85 M EUR
Jan 1, 2016
10.68 M EUR
Jan 1, 2017
6.37 M EUR
Jan 1, 2018
7.43 M EUR
Jan 1, 2019
4.65 M EUR
Jan 1, 2020
5.38 M EUR
Jan 1, 2021
5.26 M EUR
Jan 1, 2022
3.55 M EUR
The Genomic Vision Current Assets history
YEARCurrent AssetsYoY
3.55 MEUR-32.46%
5.26 MEUR-2.19%
5.38 MEUR+15.61%
4.65 MEUR-37.41%
7.43 MEUR+16.53%
6.37 MEUR-40.33%
10.68 MEUR-43.32%
18.85 MEUR-24.96%
25.12 MEUR+421.16%
4.82 MEUR+11.57%
4.32 MEUR-1.82%
4.40 MEUR
Access this data via the Eulerpool API

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

Current Assets of Genomic Vision is 3.55 M EUR in 2026.

Current Assets of Genomic Vision changed from 5.26 M EUR to 3.55 M EUR, representing a -32.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Genomic Vision

All Key Metrics — Genomic Vision